HOME >> MEDICINE >> NEWS
Gene mutations predict which lung cancers will respond to Iressa

Researchers from the Massachusetts General Hospital (MGH) Cancer Center have discovered a molecular marker that identifies lung cancer patients whose tumors will respond to treatment with the drug Iressa (gefitinib). Their findings, which will be published in the May 20 New England Journal of Medicine, are being released online today to coincide with the online release by Science of related research from Dana-Farber Cancer Institute.

"This discovery will help us significantly improve the treatment of many lung cancer patients and is also an important next step in the molecular targeting of cancer drugs," says Daniel Haber, MD, PhD, director of the MGH Cancer Center and senior author of the NEJM paper. "We're hopeful that what we have learned will eventually lead to more new drugs that will target tumor-specific mutations without affecting normal tissues."

Iressa was approved a year ago for the treatment of advanced non-small-cell lung cancer (NSCLC), a tumor that is particularly difficult to treat and is the leading cause of cancer deaths in the U.S. In a major clinical trial Iressa caused tumors to shrink significantly in only 13.6 percent of patients, but some of those responses were rapid and dramatic. As a result, the FDA approved the drug because there are no other treatment options for NSCLC patients for whom standard chemotherapy has failed.

Iressa acts by disabling the epidermal growth factor receptor (EGFR) on the surface of lung cancer cells, halting a sequence of signals that can lead to the uncontrolled growth characterizing a malignant tumor. In their search for an answer to why the drug worked so well for some NSCLC patients but was of no assistance to others, the MGH team screened tumor samples from MGH patients who participated in the Iressa clinical trial to search for mutations in the EGFR gene.

Initial analysis found mutations affecting the same area (the ATP cleft of the kinase domain) of the receptor prot
'"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
29-Apr-2004


Page: 1 2 3

Related medicine news :

1. Non-invasive and invasive breast cancers share the same genetic mutations
2. Both inherited traits and tumor mutations affect response to treatment of leukemia
3. Small increases or blips in HIV levels do not signal mutations leading to drug-resistant HIV
4. Gene mutations responsible for childhood cataracts discovered
5. Breast cancer patients with BRCA1 or 2 mutations twice as likely to have double mastectomy
6. Breast cancer patients with BRCA 1/2 mutations twice as likely to choose double mastectomy
7. Mayo Clinic researchers discover gene mutations that ignore stress, lead to heart failure
8. In 15 seconds, new test will ID presence of 25 most common mutations of cystic fibrosis
9. Northwestern on trail of gene mutations that trigger sex reversal
10. Gene mutations found that lead to prostate cancer in mice new mouse model developed to study the disease
11. New evaluation tool reliably predicts recovery from coma

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Gene mutations predict which lung cancers will respond Iressa

(Date:3/3/2015)... (PRWEB) March 03, 2015 March 3, 2015, ... the 200th episode. The episode was a unique one, not ... season, but because it featured two men who were both ... accident. At the beginning of the episode, Deierlein said to ... on my radio show, but I’m very excited that you ...
(Date:3/3/2015)... Maryland (PRWEB) March 03, 2015 ... as its North American public relations and marketing ... Manuka Lab contract because of its significant expertise ... Headquartered in Auckland, New Zealand, Manuka Lab, Limited ... clients effective, certified natural skin care solutions rooted ...
(Date:3/3/2015)... Using an “intelligent,” rather than random, ... D prescription drug coverage plans could save Medicare and ... of Pittsburgh Graduate School of Public Health analysis discovered. ... issue of the journal Health Affairs and build upon ... more than $5 billion in its Part D low-income ...
(Date:3/3/2015)... Claflin Medical Equipment, headquartered in ... has signed a new, five year contract for medical ... Under the contract, the company will provide VA Hospitals ... Indian Health Services, National Institute of Health, and other ... pricing for hospital equipment and related services. Claflin looks ...
(Date:3/3/2015)... 03, 2015 After the holiday season, ... of fitness and exercise. Community Health Center of Snohomish ... 6 ways that families in Everett, Marysville, and the ... months. , CHC says, “While it’s relatively simple ... steamed veggies, many families wonder how to keep exercise ...
Breaking Medicine News(10 mins):Health News:My Positive Perspective Releases Episode #200 With Car Accident and Coma Survivor Nick Collins 2Health News:Manuka Lab North America, Inc. Awards Cornerstone Communications, LTD North American Agency Contract 2Health News:Medicare and Patients with Schizophrenia Could Save $150 Million on Part D Plans 2Health News:Medicare and Patients with Schizophrenia Could Save $150 Million on Part D Plans 3Health News:Claflin Medical Equipment (CME) Announces New 5 Year Contract with the Department of Veterans Affairs (VA) 2Health News:6 Wintertime Weight Loss Tips for Family Fitness Presented by Community Health Center of Snohomish County in Recent Article 2
(Date:3/3/2015)...  Cyberonics, Inc. (NASDAQ: CYBX ), a ... management of epilepsy, today announced it will participate in ... 2015, in Miami . ... Officer, will speak at 1:05 PM Eastern Time.  The ... and no formal materials will be presented.  A live ...
(Date:3/3/2015)... March 3, 2015  The eleventh annual Tucson Symposium ... the world,s top research scientists, academics, oncologists and pathologists ... and learn about new outcomes in patient treatments that ... Each year Ventana Medical Systems, Inc. (Ventana), ... the Tucson Symposium at the Hilton El Conquistador in ...
(Date:3/3/2015)... , March 3, 2015 /CNW/ - ChipCare Corporation, ... handheld, blood-testing platform for HIV and other infectious ... Series A financing to bring its first-generation product ... generation products. (Photo: http://photos.prnewswire.com/prnh/20150303/179107 ... health settings to simple, accurate and affordable diagnostic ...
Breaking Medicine Technology:Global scientific collaborators to explore latest pathology and oncology advancements at Tucson Symposium 2ChipCare Closes Oversubscribed $5 Million Series A Financing 2ChipCare Closes Oversubscribed $5 Million Series A Financing 3
Cached News: